Today's special on the anticancer menu: Immunomodulation by antifolates

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Pemetrexed is widely employed for the clinical management of mesothelioma and non–small cell lung carcinoma, largely based on its ability to curtail folate metabolism in highly proliferating cells. Recent preclinical findings suggest that the therapeutic efficacy of pemetrexed may involve an unsuspected immunologic component.

Original languageEnglish
Pages (from-to)6890-6892
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number23
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Today's special on the anticancer menu: Immunomodulation by antifolates'. Together they form a unique fingerprint.

Cite this